StockData

NextCure, Inc. (NXTC) company profile

NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$6.68+0.28 (+4.37%)

Close on Nov 16, 2026Market cap $30.58MP/E –Yield 0.00%

About NextCure

Pharmaceutical Preparations, SIC 2834

NextCure, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing targeted therapies, particularly antibody-drug conjugates, to treat cancer patients whose disease progresses or fails to respond to existing treatments. The company focuses on biological pathways, biomarkers, and cellular interactions within the tumor microenvironment. Its lead product candidates in Phase 1 clinical development include SIM0505, an antibody-drug conjugate directed against cadherin-6, and LNCB74, an antibody-drug conjugate targeting B7-H4. Additionally, the company is seeking strategic partners to develop its other clinical oncology candidates and preclinical non-oncology programs. Because its therapeutics are investigational biologics in clinical trials, the company does not yet market commercial products to paying customers.

The company operates globally through collaborative licensing and co-development partnerships spanning the United States, China, and other international regions. It maintains a dedicated, single-use current Good Manufacturing Practice production facility with a capacity of 2,000 liters, although internal manufacturing operations were paused following an operational restructuring. The provided text does not identify NextCure's headquarters location.

Summary of the business section of NextCure's latest annual report, written by StockData.

Company profile

Company

Legal name
NextCure, Inc.
Headquarters
Baltimore, MD
Address
2850 Quarry Lake Drive, Suite 280 21209
Phone
(240) 399-4900
Employees
40, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst& Young LLP, Baltimore, Maryland

Stock & identifiers

Ticker
NXTC
Exchange
Nasdaq
IPO date
May 9, 2019
Shares outstanding
5M, Jul 31, 2026
Public float
$12.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-12 reverse, Jul 14, 2025
SEC CIK
1661059
CUSIP
65343E207
ISIN
US65343E2072
FIGI
BBG00BTH5153
Share class FIGI
BBG00BTH5162
LEI
549300Y5PR6RJR1STI24
EIN
47-5231247

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Michael RichmanPresident & CEO, Director385,869
Udayan GuhaChief Medical Officer–
Kevin G. ShawSr VP, General Counsel–
Sourav KunduSr VP, Dev. & Mfg.–
Timothy MayerChief Operating Officer–
Steven P. CobournChief Financial Officer–
Sol LangermannChief Scientific Officer37,342
Elaine V. JonesDirector–
Anne Elizabeth BorgmanDirector–
Ellen FeigalDirector–
Stephen W. WebsterDirector–
John G. HoustonDirector–
David S. KabakoffDirector62,237

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$941.69K$1.07M$636.21K$84–
FY2024$1.51M$1.14M$876.46K$55–
FY2023$1.04M$885.07K$689.76K$81–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Michael Richman
President and Chief Executive Officer
$609.26K$189.17K$122.00K$21.26K$941.69K-38%
Udayan Guha, M.D., Ph.D.
Chief Medical Officer
$474.19K$72.67K$76.20K$16.18K$639.24K–
Timothy Mayer, Ph.D.
Chief Operating Officer
$468.43K$72.67K$75.10K$16.98K$633.18K-27%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 9, 2019
Offer price
$15.00
Securities offered
5,000,000
Gross proceeds
$75.00M
Exchange
Nasdaq
First trading day
May 9, 2019
First-day close
$19.90+32.7%
Lock-up ends (est.)
Nov 5, 2019

“The initial public offering price is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 40 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?